Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

21 trials with published results (20%)

Research Maturity

55 completed trials (53% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.9%

3 terminated out of 104 trials

Success Rate

94.8%

+8.3% vs benchmark

Late-Stage Pipeline

10%

10 trials in Phase 3/4

Results Transparency

38%

21 of 55 completed with results

Key Signals

21 with results95% success

Data Visualizations

Phase Distribution

78Total
Not Applicable (21)
Early P 1 (1)
P 1 (28)
P 2 (18)
P 3 (5)
P 4 (5)

Trial Status

Completed55
Unknown16
Active Not Recruiting12
Recruiting11
Withdrawn3
Terminated3

Trial Success Rate

94.8%

Benchmark: 86.5%

Based on 55 completed trials

Clinical Trials (104)

Showing 20 of 20 trials
NCT03696784Phase 1Active Not Recruiting

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03922724Phase 2Active Not Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT00006150Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

NCT00001406RecruitingPrimary

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

NCT06173544Not ApplicableCompleted

HIV Engagement and Adolescent Depression Support (HEADS-UP)

NCT07699380Phase 2Recruiting

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT04656873Completed

Immuno-Oncology Database and Bioregistry

NCT02690545Phase 1Active Not Recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

NCT06353087Active Not Recruiting

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

NCT02579967Phase 2Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT03602157Phase 1Active Not Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT03016377Phase 1Active Not Recruiting

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT02663297Phase 1Active Not Recruiting

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT04663204Phase 2Recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

NCT05787574Phase 2Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

NCT05565248Phase 1Terminated

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

NCT02640014Not ApplicableCompleted

Oral Immunotherapy in Food Allergy in Finland

NCT04339777Phase 2Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT05969821Not Yet RecruitingPrimary

Clonal Hematopoiesis of Immunological Significance

NCT03663933Phase 2Active Not Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Scroll to load more

Research Network

Activity Timeline